For the millions of people living with prurigo nodularis, a chronic skin condition that causes relentless, debilitating itch and hard nodules across the body, meaningful relief has historically been elusive. Until recently, there were no FDA-approved treatments specifically for this condition, leaving patients and their doctors to cobble together off-label therapies with inconsistent results. That changed with the approval of two targeted biologic therapies — Dupixent (dupilumab), the first-ever FDA-approved treatment for prurigo nodularis, and Nemluvio (nemolizumab-ilto), a first-in-class IL-31 inhibitor approved in August 2024 that has shown remarkable efficacy in clinical trials. In the OLYMPIA trials, up to 56 percent of patients treated with nemolizumab achieved a clinically meaningful reduction in itch intensity at week 16, compared to just 16 percent on placebo — and long-term data extending to three years shows sustained relief for the vast majority of patients.
The connection between chronic itch conditions and brain health is more significant than many people realize. Persistent, uncontrolled pruritus disrupts sleep, drives anxiety and depression, and can accelerate cognitive decline — concerns that are especially pressing for older adults and those already managing neurodegenerative conditions. For caregivers supporting a loved one with dementia who also suffers from prurigo nodularis, the constant scratching and agitation caused by unrelenting itch can be mistaken for behavioral symptoms of dementia itself, complicating care and diagnosis. This article examines how these new treatments work, what the clinical evidence actually shows, how quickly patients can expect relief, and what the long-term outlook looks like. We will also address the practical realities of choosing between available therapies and the particular considerations for older adults and those with cognitive impairment.
Table of Contents
- What Are the New Drugs for Prurigo Nodularis and How Do They Relieve Debilitating Itch?
- How Effective Is Nemolizumab According to Clinical Trial Results?
- How Quickly Does Nemolizumab Start Working?
- What Does Long-Term Treatment With Nemolizumab Look Like?
- What Happens When the First Treatment Does Not Work?
- Why Prurigo Nodularis Matters in Dementia and Brain Health Care
- The Future of Prurigo Nodularis Treatment
- Conclusion
- Frequently Asked Questions
What Are the New Drugs for Prurigo Nodularis and How Do They Relieve Debilitating Itch?
Prurigo nodularis has long been one of dermatology’s most frustrating conditions to treat. The disease creates a vicious itch-scratch cycle: intensely itchy, firm nodules form on the skin, scratching damages the skin further, and new nodules develop in response. Before targeted therapies arrived, patients often relied on potent topical steroids, phototherapy, or immunosuppressants — none of which were designed for the specific inflammatory pathways driving prurigo nodularis. Dupixent (dupilumab), manufactured by Regeneron and Sanofi, was the first to break through. It works as an interleukin-4 receptor alpha antagonist, blocking a key signaling pathway involved in type 2 inflammation. Administered as a 300 mg subcutaneous injection every two weeks after an initial 600 mg loading dose, it was the first drug to earn FDA approval specifically for prurigo nodularis in adults.
However, the more recent arrival, Nemluvio (nemolizumab-ilto) from Galderma, targets a different and arguably more specific mechanism. Nemolizumab is the first monoclonal antibody to inhibit interleukin-31, a neuroimmune cytokine now recognized as a central driver of itch signaling, fibrosis, inflammation, and altered skin cell development in prurigo nodularis patients. Its FDA approval in August 2024 followed a breakthrough therapy designation in December 2019 and a priority review granted in February 2024 — regulatory milestones that reflect how urgently a targeted therapy was needed. The distinction between these two drugs matters. Dupilumab casts a broader anti-inflammatory net by targeting IL-4 and IL-13 pathways, while nemolizumab goes after IL-31 directly — the cytokine most closely tied to the neurological sensation of itch itself. For patients whose primary burden is the itch rather than widespread inflammation, that specificity may translate into faster and more targeted relief, though individual responses vary and direct head-to-head trial data between the two drugs is not yet available.
How Effective Is Nemolizumab According to Clinical Trial Results?
The OLYMPIA clinical trial program provides the most robust evidence for nemolizumab’s efficacy in prurigo nodularis. In the OLYMPIA 1 trial, 56 percent of patients receiving nemolizumab achieved at least a 4-point reduction in itch intensity on the Peak Pruritus Numerical Rating Scale at week 16, compared to just 16 percent of patients on placebo. The OLYMPIA 2 trial replicated these findings, with 49 percent of nemolizumab patients reaching the same threshold versus 16 percent on placebo. These are not marginal improvements — a 4-point reduction on the itch scale represents a shift from severe, life-disrupting itch to a level many patients describe as manageable. What the sleep data reveals is equally important, and particularly relevant for readers concerned about brain health. Chronic sleep deprivation is a well-established risk factor for cognitive decline and is closely linked to worsening dementia symptoms.
In OLYMPIA 1, 50 percent of nemolizumab patients achieved a clinically meaningful improvement in sleep disturbance at week 16, compared to 12 percent on placebo. In OLYMPIA 2, the numbers were 52 percent versus 21 percent. For older adults struggling with both prurigo nodularis and cognitive concerns, restoring sleep quality is not a secondary benefit — it is a critical outcome that can influence the trajectory of brain health. However, it is important to note that these results come from controlled clinical trial settings with carefully selected patient populations. Real-world outcomes may differ, and not every patient in the trials responded. Roughly half of patients in the OLYMPIA 1 trial did not reach the primary itch endpoint, meaning there remains a substantial subset for whom nemolizumab alone may not be sufficient. Additionally, clinical trials typically exclude patients with significant comorbidities, including advanced dementia, so how well these results generalize to the most complex patient populations remains an open question.
How Quickly Does Nemolizumab Start Working?
One of the most striking findings from the OLYMPIA trials is how rapidly nemolizumab begins to reduce itch. Significant improvements in itch intensity were observed as early as 48 hours after the initial treatment — a timeline that is unusually fast for a biologic therapy. At the 48-hour mark, 17.2 percent of prurigo nodularis patients on Nemluvio showed measurable improvement, compared to just 3.7 percent on placebo. While 17 percent may sound modest, consider what it means for someone who has been scratching uncontrollably for months or years: even partial relief within two days can break the itch-scratch cycle and begin the process of skin healing. These improvements steadily increased through day 14 and continued building over the full treatment course.
this rapid onset is particularly relevant in care settings where a patient’s scratching behavior is causing secondary complications — skin infections, wounds that will not heal, or behavioral agitation in patients with cognitive impairment. A caregiver managing an older adult with both dementia and prurigo nodularis, for example, may notice reduced scratching and improved comfort within the first week or two of treatment, which can meaningfully reduce caregiver burden and prevent the cascade of complications that chronic scratching creates. That said, rapid onset does not mean instant resolution. The full benefit of nemolizumab unfolds over weeks and months. Patients and caregivers should set realistic expectations: early itch reduction is encouraging, but nodule clearance and complete symptom control typically take longer to achieve.
What Does Long-Term Treatment With Nemolizumab Look Like?
A common concern with any new medication, especially in older populations, is whether it remains effective and safe over time. The OLYMPIA open-label extension study provides reassuring long-term data extending up to three years. At week 100, more than 90 percent of evaluable patients had achieved at least a 4-point improvement in itch intensity, and more than 70 percent were itch-free or nearly itch-free. The safety profile remained well-tolerated throughout the extended treatment period, with clinically meaningful improvements sustained in itch intensity, skin lesion appearance, and overall quality of life. When comparing treatment timelines, the difference between short-term trial data and long-term extension data is notable. At week 16 in the controlled trials, roughly half of patients hit the primary endpoint.
By week 100 in the open-label extension, that number climbed above 90 percent. This suggests that nemolizumab’s benefits continue to build well beyond the initial treatment phase — a pattern consistent with gradual resolution of the underlying inflammatory process rather than simple symptom suppression. The tradeoff, of course, is commitment. Long-term biologic therapy requires ongoing injections, regular monitoring, and sustained insurance coverage or financial assistance. For families already navigating the complexities of dementia care, adding another chronic medication demands careful coordination. But for patients whose quality of life has been devastated by uncontrolled itch, the evidence suggests that sustained treatment delivers sustained results — and that the alternative of untreated prurigo nodularis carries its own substantial costs in terms of sleep loss, skin damage, infection risk, and emotional distress.
What Happens When the First Treatment Does Not Work?
Not every patient responds adequately to the first biologic therapy they try, and emerging real-world evidence is beginning to clarify the sequencing question. A 24-week real-world study published in 2026 confirmed that nemolizumab provides rapid and sustained itch relief with gradual lesion improvement in prurigo nodularis patients treated outside of controlled trial settings — an important validation that clinical trial results translate to everyday practice. Perhaps more significant is the documented evidence that nemolizumab has been effective in patients who had persistent pruritus or lesions after dupilumab treatment. This suggests that nemolizumab may serve as a viable second-line option for patients who do not respond fully to Dupixent, likely because it targets a different inflammatory pathway.
For clinicians and caregivers, this means that a poor response to one biologic does not mean all biologics will fail — there is a rational basis for switching. However, a word of caution is warranted. The evidence for sequencing these treatments is still limited to case reports and small studies rather than large randomized trials. There are currently no established guidelines dictating when to switch from dupilumab to nemolizumab or vice versa, and insurance coverage for a second biologic after failure of the first can be difficult to obtain. Patients and caregivers should work closely with a dermatologist experienced in treating prurigo nodularis to navigate these decisions, and should be prepared for potential delays in authorization.
Why Prurigo Nodularis Matters in Dementia and Brain Health Care
The intersection of chronic itch and cognitive impairment creates a particularly difficult clinical scenario. A patient with moderate Alzheimer’s disease who also develops prurigo nodularis may not be able to articulate the severity of their itch, may scratch compulsively without understanding why, and may resist examinations or treatments due to confusion or agitation. Caregivers and clinicians may attribute the behavioral changes — restlessness, irritability, disrupted sleep, picking at skin — to dementia progression rather than recognizing an undertreated dermatological condition.
Screening for prurigo nodularis and other chronic itch conditions should be part of comprehensive care for older adults with cognitive impairment, especially when new behavioral symptoms emerge. The availability of effective, targeted treatments like nemolizumab and dupilumab makes identification even more important, because these are now treatable causes of suffering rather than conditions to be endured. Health Canada’s January 2026 approval of nemolizumab for adults with moderate-to-severe prurigo nodularis not adequately controlled by topical therapies further expands access for patients in North America.
The Future of Prurigo Nodularis Treatment
The approval of two targeted biologics within a few years has transformed a condition that previously had no approved treatments into one with a growing therapeutic toolkit. Research into IL-31 and related neuroimmune pathways continues, and the success of nemolizumab has validated the concept that targeting itch-specific signaling — rather than broad immunosuppression — can produce meaningful results. Future investigations will likely explore combination approaches, biomarkers that predict which patients will respond best to which therapy, and the potential role of these drugs in other chronic itch conditions that share similar inflammatory mechanisms.
For the brain health community, these developments underscore a broader principle: treating the whole patient means looking beyond cognitive symptoms. Chronic itch is not a minor annoyance. It destroys sleep, fuels anxiety and depression, and degrades quality of life in ways that directly intersect with cognitive health. The arrival of effective treatments for prurigo nodularis is a meaningful step forward — not just for dermatology, but for anyone caring for an older adult whose unexplained agitation or sleeplessness might have a treatable skin condition at its root.
Conclusion
The FDA approvals of Dupixent and Nemluvio represent a genuine turning point for people living with prurigo nodularis. For the first time, patients have access to targeted biologic therapies backed by strong clinical evidence — with nemolizumab’s OLYMPIA trials demonstrating itch reduction in up to 56 percent of patients at 16 weeks and over 90 percent at nearly two years, along with rapid onset within 48 hours and sustained long-term efficacy through three years of follow-up. Real-world studies published in 2026 have confirmed these benefits extend beyond controlled trial settings, and evidence that nemolizumab can help patients who did not respond fully to dupilumab provides a rational path forward when first-line treatment falls short.
For caregivers and families in the dementia care space, the message is clear: chronic itch conditions like prurigo nodularis are underrecognized contributors to sleep disruption, behavioral changes, and diminished quality of life in older adults with cognitive impairment. If a loved one is exhibiting unexplained scratching, skin nodules, agitation, or worsening sleep, a dermatological evaluation is warranted. These are no longer conditions without good treatment options. Speaking with a dermatologist about whether dupilumab or nemolizumab may be appropriate — and understanding that response may improve over months of sustained treatment — is a concrete step caregivers can take today.
Frequently Asked Questions
What is prurigo nodularis?
Prurigo nodularis is a chronic skin condition that causes intensely itchy, hard nodules on the skin. It creates a self-perpetuating itch-scratch cycle in which scratching leads to more nodule formation and worsening symptoms. Prior to recent drug approvals, there were no FDA-approved treatments specifically for this condition.
How does Nemluvio (nemolizumab) differ from Dupixent (dupilumab) for prurigo nodularis?
Both are injectable biologic therapies, but they target different parts of the immune system. Dupixent blocks the IL-4 receptor alpha, addressing broad type 2 inflammation. Nemluvio is the first drug to specifically inhibit interleukin-31, a neuroimmune cytokine considered a key driver of the itch signal in prurigo nodularis. No head-to-head trials comparing the two have been published, so the choice between them should be made with a dermatologist based on individual patient factors.
How quickly does nemolizumab start relieving itch?
Clinical trial data showed significant itch improvements as early as 48 hours after the first dose, with 17.2 percent of patients on Nemluvio showing improvement at that time point compared to 3.7 percent on placebo. Improvement continued to increase steadily through day 14 and beyond, with full benefits typically emerging over weeks to months.
Is nemolizumab effective long-term?
Yes. Long-term data from the OLYMPIA open-label extension study demonstrated sustained disease control up to three years. At week 100, more than 90 percent of evaluable patients had achieved a clinically meaningful reduction in itch, and more than 70 percent were itch-free or nearly itch-free, with a well-tolerated safety profile maintained throughout.
Can nemolizumab help if dupilumab did not work well enough?
Emerging evidence suggests yes. Cases have been documented in which nemolizumab was effective in patients who had persistent itch or skin lesions after dupilumab treatment. Because the two drugs target different inflammatory pathways, a lack of response to one does not predict failure with the other. However, the evidence for this sequencing approach is still limited and insurance authorization for a second biologic can be challenging.
Why is prurigo nodularis relevant to dementia and brain health?
Chronic, uncontrolled itch disrupts sleep, increases anxiety and depression, and can cause behavioral changes such as agitation and restlessness — all of which can worsen cognitive function and complicate dementia care. In patients with cognitive impairment, prurigo nodularis symptoms may be misattributed to dementia progression rather than recognized as a treatable dermatological condition.
